Abstract: The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to ?v?3 integrin antagonists via preferred linking units which can be selectively cleaved by elastase, i.e. by an enzyme which can especially be found in tumour tissue. The preferred linking units provide sufficient stability of the conjugate of cytostatic and ?v?3 integrin antagonist in biological fluids and, at the same time, the desired intracellular action within tumour cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.

Abstract: The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to ?v?3 integrin antagonists via preferred linking units. The preferred linking units guarantee serum stability of the conjugate of cytostatic and ?v?3 integrin antagonist and at the same time the desired intracellular action in tumour cells as a result of their enzymatic or hydrolytic cleavability with release of the cytostatic.

Abstract: The present invention relates to novel substituted &agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.

Abstract: The invention relates to cyclopentabenzofuran derivatives and their use preparation, the use of cyclopentabenzofuran derivatives for the production of a medicament for the therapy of NF-&kgr;B-dependent diseases and medicaments which contain the cyclopentabenzofuran derivatives.

Abstract: The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to &agr;v&bgr;3 integrin antagonists via preferred linking units which can be selectively cleaved by elastase, i.e. by an enzyme which can especially be found in tumour tissue. The preferred linking units provide sufficient stability of the conjugate of cytostatic and &agr;v&bgr;3 integrin antagonist in biological fluids and, at the same time, the desired intracellular action within tumour cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.

Abstract: The present invention relates to cytostatics which have a tumor-specific action as a result of linkage to &agr;v&bgr;3 integrin antagonists via preferred linking units which can be selevtively cleaved by enzymes such as metallo matrixproteases (MMPs), i.e. by enzymes which can especially be found in tumor tissue. The preferred linking units guarantee the serum stability of the conjugate of cytostatic and &agr;v&bgr;3 integrin antagonist and, at the same time, the desired intracellular action within tumor cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.

Abstract: The present invention relates to conjugates of cytostatics and N-thiocarbonyl-modified amino acids or peptides, processes for their preparation and their use as medicaments, in particular in connection with carcinomatous disorders.

Abstract: The present invention relates to glycoconjugates of camptothecin derivatives in which at least one carbohydrate component is linked via suitable spacers with the A or B ring of a camptothecin derivative. The invention furthermore relates to processes for preparing the compounds according to the invention and to their use as medicaments, in particular in connection with cancer.

Abstract: The invention relates to polynucleotides which contain pseudorabies virus sequences, in particular sequences from the gII region of PRV, in the antisense orientation, their preparation and their use.

Abstract: The present invention relates to the targeted blocking of the genetic information of the viral messenger ribonucleic acid (mRNA) for virus replication (e.g. of HIV) in transfected, haematopoietic cells with particularly suitable expression systems, which express a complementary "antisense RNA".

Abstract: An apparatus for cultivating immobilized micro-organisms consisting of a fluidized bed reactor with fittings for gassing and a retainer system for the immobilized biocatalysts. The fluidized bed reactor is characterized in that the fittings for gassing consist of several segments with gas outlets arranged on the base of the fluidized bed reactor, which admit gas alternately or cyclically. A central gas outflow opening, pointing upwards, can be provided in the fluidized bed reactor as a further gassing unit. The method of operating the fluidized bed is characterized in that circulating gassing occurs in the reactor by means of sequential opening of the gas inflow openings of the segment-shaped fittings. In addition, switches may occur from the central gassing unit to gassing by means of the segment-shaped fittings or vice-versa.

Abstract: A process for the preparation of glycoproteins and proteins from cultures of archaebacteria, comprising culturing archaebacteria, isolating glycoprotein and/or protein from the archaebacteria or their cell walls, enzymatically degrading the glycoprotein and/or protein, purifying and isolating the degradation products, and separating those fractions in the individual purification steps based on the biological activity of the fraction. The products increase the body's defenses against infection.

Abstract: Waste water and/or outgoing air are purified by contact with a polyurethane hydrogel containing surface active coal, a polymer having cationic groups and cells having enzymatic activity and being capable of growth.

Abstract: A biologically active composition is prepared comprising a polyurethane hydrogel containing surface active coal, a polymer having cationic groups and cells having enzymatic activity and being capable of growth. The composition is used for purifying waste water and outgoing air.

Abstract: A process for the production of a storage-stable preparation of micro-organisms, starting from a mixed culture of micro-organisms, which is capable to degrade products of industrial organic syntheses, which comprises that the culture conditions of an active mixed culture enriched in the customary manner are optimized, with the addition of the product to be degraded, in the customary manner according to the rate of degradation of the product and this mixed culture is converted in at least two passes into a stabilized activated mixed culture under the optimum conditions thus determined, and the culture thereby obtained is rendered storage-stable, its activity being maintained.